Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection

Anaerobe

Volumn 15, Issue 6, 2009, Pages 234-236

  Citron, D M ^a   Babakhani, F ^b   Goldstein, E J C ^a   Nagaro, K ^c   Sambol, S ^c   Sears, P ^b   Shue, Y K ^b   Gerding, D N ^c,d  

^a RM Alden Research Lab ^*  (United States)

^b Optimer Pharmaceuticals Inc   (United States)

^c HINES VA HOSPITAL   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

CDI; Clostridium; Difficile; Fidaxomicin; OPT 80; PAR 101

Indexed keywords

METRONIDAZOLE; TIACUMICIN B; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG TREATMENT FAILURE; HUMAN; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; CLOSTRIDIUM DIFFICILE; DNA RESTRICTION ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GLYCOSIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; RIBOTYPING; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM; CLOSTRIDIUM DIFFICILE;

EID: 70549097125     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2009.09.005     Document Type: Article

References (21)

1. Kelly C.P., and LaMont J.T. Clostridium difficile: more difficult than ever. N Engl J Med 359 (2008) 1932-1940
2. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
3. Labbé A.C., Poirier L., Maccannell D., Louie T., Savoie M., Béliveau C., et al. Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52 (2008) 3180-3187
4. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., et al. An epidemic, toxin gene-varient strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441
5. Brazier J.S., Raybould R., Patel B., Duckworth G., Pearson A., Charlett A., et al. Distribution and antimicrobial susceptibility patterns of Clostridium difficile PCR ribotypes in English Hospitals, 2007-2008. Eurosurveillance 13 (2008) 1-5
6. Kuijper E.J., Barbut F., Brazier J.S., Kleinkauf N., Eckmanns T., Lambert M.L., et al. Update of Clostridium difficile infection due to PCR Ribotype 027 in Europe, 2008. Eurosurveillance 13 (2008) 1-7
7. Dupuy B., Govind R., Antunes A., and Matamouros S. Clostridium difficile synthesis is negatively regulated by tcdC. J Med Microbiol 57 (2008) 685-689
8. Warny M., Pepin J., Fang A., Killgore G., Thompson A., Brazier J., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 (2005) 1079-1084
9. Nelson, R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults (Review). Cochrane Review, Cochrane Library; 2008, vol. 1.
10. Aslam S., Hamill R.J., and Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 5 (2005) 549-557
11. Zar F.A., Bakkanagari S.R., Moorthi K.M., and Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007) 302-307
12. Hecht D.W., Galang M.A., Sambol S.P., Osmolski J.R., Johnson S., and Gerding D.N. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 51 (2007) 2716-2719
13. Credito K.L., and Appelbaum P.C. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 48 (2004) 4430-4434
14. Finegold S.M., Molitoris D., Vaisanen M.L., Song Y., Liu C., and Bolaños M. In vitro Activities of OPT-80 and Comparator Drugs against Intestinal Bacteria. Antimicrob Agents Chemother 48 (2004) 4898-4902
15. Louie T., Miller M., Donskey C., Mullane K., and Goldstein E.J.C. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection. Antimicrob Agents Chemother 53 (2009) 223-228
16. CLSI (NCCLS) M11-A7, Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard. Seventh ed. 2007.
17. Clabots C.R., Johnson S., Bettin K.M., Mathie P.A., Mulligan M.E., Schaberg D.R., et al. Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems. J Clin Microbiol 31 (1993) 1870-1875
18. Brazier J.S., Raybould R., Patel B., Duckworth G., Pearson A., Charlett A., et al. Distribution and Antimicrobial Susceptibility Patterns of Clostridium difficile PCR Ribotypes in English Hospitals, 2007-2008. Eurosurveillance 41 (2008) 1-5
19. Labbé, A, Maccannell, D, Pépin, J, Louie, T, Weiss, K, Laverdiere, M. Abstract, E-1435, 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005, Washington, DC.
20. Viropharma, Complete Prescribing Information, Vancocin Oral Capsules; 2005.
21. Bolton R.P., and Culshaw M.A. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27 (1986) 1169-1172